Dia Beta Labs Ltd

Dia Beta Labs Ltd

Biotechnology Research

Target-led management of the causes of metabolic disease

About us

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Coleraine
Type
Privately Held
Founded
2022
Specialties
Diabetes, Peptide Development, Metabolic Disease, Obesity, and Peptide Therapeutics

Locations

Employees at Dia Beta Labs Ltd

Updates

Similar pages

Funding

Dia Beta Labs Ltd 1 total round

Last Round

Grant

US$ 32.8K

Investors

INVENT
See more info on crunchbase